Vandetanib is proposed by current DR analysis as an inhibitor of the growth factor VEGFA, which is overexpressed in late MCL stages (III/IV) compared to newly diagnosed MCL cases (MCL(e)toMCL). Here, VEGFA is linked to mantle cell lymphoma.